Saul Howard Perloff
Norton Rose Fulbright US LLP
Related services and key industries
As a partner in the Intellectual Property Group and the head of the advertising practice, Saul Perloff represents domestic and international clients in advertising and unfair competition litigation under the Lanham Act and state laws as well as in other complex commercial disputes. He also counsels pharmaceutical, food, device, consumer product, biotechnology and other clients on advertising and labeling compliance as well as brand protection strategies.
Saul has successfully prosecuted and defended disputes involving false advertising, unfair competition and trademark/trade dress and patent infringement as well as antitrust, TCPA and Qui Tam actions in more than fifteen states across the country. He also represents clients in government investigations, arbitrations and NAD proceedings.
From 1992 to 1995, he served as a JAG officer and member of the Chief Counsel's Honor Program in the US Army Corps of Engineers.
JD, cum laude, University of Pennsylvania Law School, 1991
AB, Princeton School of Public and International Affairs, Princeton University, 1988
During his second year of law school (1989-1990), Saul attended L'Institute D'Etudes Politiques de Paris on a Rotary International Scholarship.
Saul is a member of the California and Texas Bars. He is admitted to practice before the Supreme Court of the United States, the U.S. Courts of Appeals for the Fifth, Ninth and Eleventh Circuits and the U.S. District Courts for the Eastern, Northern, Southern and Western Districts of Texas, the Central, Eastern and Northern Districts of California and the Eastern District of Wisconsin.
- California State Bar
- Texas State Bar
Saul has represented a wide range of clients as lead counsel in advertising litigation across the country including the following:
- A major manufacturer of personal protective equipment (PPE) against companies for trademark infringement, false advertising and price gouging during a global pandemic. The defendants agreed to a consent judgment disgorging their profits as well as a permanent injunction.
- The leading US producers of pipeline components against a foreign competitor falsely advertising its products as ASTM compliant. After a 2-week trial, the jury entered a unanimous, multi-million dollar verdict for our clients and the court subsequently entered a permanent injunction and recall.
- A major publisher of financial news in a TCPA class action. After completing discovery,the court entered summary judgment on our client's behalf and dismissed the case in its entirety.
- The global leader in non-invasive cancer testing and bioinformatics against a competitor that disparaged the client's testing and falsely claimed to offer a superior test. After accelerated discovery in preparation for a preliminary injunction hearing, the case settled on favorable terms including a significant payment to the client.
- The developer of a genetically engineered forage crop against a competitor falsely claiming its conventional seed offered similar benefits to the client's. After discovery, the case settled on favorable terms for the client.
- A Europe-based pharmaceutical company in a qui tam action brought by a former employee who alleged the client's marketing of its leading products was misleading. After delivering a presentation to the California Department of Insurance, the state elected not to intervene. The case later settled for less than defense costs.
- World leading food company against a competitor falsely advertising its products as equivalent to the clients' branded prescription medical foods. After a two-week jury trial the case settled on favorable terms including a signififcant payment to the client..
- Counsel of record for International Trademark Association (INTA) as amicus curiae to United States Supreme Court, in Pom Wonderful LLC v. The Coca-Cola Company, No. 12-761.
- Leading biotech tools company against a competitor that falsely claimed a study showed its gene analysis system was superior to the client's. After initial discovery, the case settled on favorable terms that required the defendant, among other things, to remove all references to the comparison study and to recall and destroy all materials related to the study.
- Major international pharmaceutical company against a competitor that falsely advertised allegedly "generic" versions of the client's brand name pancreatic enzyme drugs. After the court denied the defendants' motion for summary judgment the case settled on terms favorable to the client including a significant payment to the client..
- Manufacturer of the only FDA-approved inhaled antibiotic treatment for cystic fibrosis patients in a Lanham Act suit against a competing company and three compounding pharmacies. After obtaining a temporary restraining order against the defendants, the parties reached a settlement under which the defendants were required to market their treatment with disclaimers warning doctors and patients that their therapy was not clinically proven.
- Manufacturer of a brand-name wound care ointment in a pair of Lanham Act cases against companies who falsely advertised their products as "generic" alternatives to the brand. After securing preliminary injunctions against both defendants and defeating multiple dispositive motions, the cases proceeded to trial. At the conclusion of each 3-week jury trial, the court entered significant monetary judgments and injunctions against both defendants.
- Leading consumer product company in suit against the supplier of a "store-brand" version of the client's top-selling oral rinse. After conducting preliminary discovery, the parties reached a settlement that included a permanent injunction requiring the defendant to withdraw its offending product from the market.
- Legal 500 US, recommended lawyer, Intellectual Property: Trademarks: Litigation, The Legal 500, 2015 - 2018
- Legal 500 US, recommended lawyer, Media technology and telecoms - Advertising and marketing: litigation, The Legal 500, 2015 - 2020
- Acritas Star, Acritas, 2017 - 2020
- The Best Lawyers in America, Best Lawyers, 2013 - 2021
- Texas Super Lawyer, Intellectual Property Litigation, Thomson Reuters, 2013 - 2019
- AV Preeminent Rated Lawyer, LexisNexis Martindale-Hubbell
- Co-author, "Advertising and promotion in the US healthcare marketplace during COVID-19 crisis," Norton Rose Fulbright - Legal update, March, 2020
- Co-author, "'Milking' The 1st Amendment To Defend Food Label Claims," Law360, April 26, 2017
- Co Author, "Intra-Circuit split should give advertisers pause," Norton Rose Fulbright - Legal update, September 26, 2016
- "USOC's aggressive policing of Olympic trademarks," Norton Rose Fulbright - Legal update, August 3, 2016
- Co Author, "Amarin and FDA settle off-label suit," Norton Rose Fulbright - Legal update, March 10, 2016
- "FDA proposes move to electronic labeling," Norton Rose Fulbright - Legal update, December 19, 2014
- Co Author, "Supreme Court decision resolves circuit split on prudential standing in Lanham Act disputes," Norton Rose Fulbright - Legal update, March 2014
- Co Author, "Medical experts cast doubt on multivitamin health benefits - Are enforcement efforts and consumer class actions far behind?," Norton Rose Fulbright - Legal update, January 13, 2014
- Co Author, "Medical experts cast doubt on multivitamin health benefits," December 23, 2013
- Co Author, "Drug Company Asserts Right to Require FDA to Protect Market Exclusivity of Brand Drugs," Washington Health Care Update, August 10, 2012
- Co Author, "Fulbright's 8th Annual Litigation Trends Report," The International Law Firm of Fulbright & Jaworski - Litigation, October 18, 2011
- Co Author, "Another Signal That the DOJ Is Serious About Antitrust: Payments in Patent Settlements May Be Unlawful," Fulbright Briefing, July 10, 2009
- Co Author, "United States Supreme Court Grants Certiorari in Wyeth V. Levine, No. 06-1249, to Consider Preemptive Scope of FDA Approval of Prescription Drug Labeling," Fulbright Briefing, January 23, 2008
- "Understanding and Achieving the Goals of the Client," Inside the Minds: Advertising and Marketing Litigation Best Practices, 2008
- Co Author, "Free Drug Samples Limit Cost to Settle Drugmaker Antitrust Action," Fulbright Briefing, December 7, 2007
- "Understanding and Achieving the Goals of the Client?," Advertising and Marketing Litigation Best Practices: Leading Lawyers on Preventing Conflicts, Mitigating Risks, and Deciding When to Settle vs. Litigate (Inside The Minds), November 16, 2007
- "Federal Circuit Defines When Preclinical Drug Research Constitutes Patent Infringement in Holding That Merck Did Not Infringe an Integra Patent,"
Fulbright Briefing, August 1, 2007
- Guest, "Brands and the Law: An Interview with Saul Perloff," The B2B Brand Podcast, June 2020
- Presenter/Moderator, "2019 Litigation Trends Annual Survey," ACC (South/Central Texas Chapter), San Antonio, TX, February 2020
- Presenter, "Protecting Your Brand Against False Advertising," Texas Bar Association 16th Annual Advanced In-House Counsel Course, Austin, TX, August 2017
- Presenter, "The First Amendment & FDA Restrictions On Commercial Speech," Momentum Food & Beverage Webinar Series, June 2016
- Panelist, "It's a Brave New World: Real World Strategies for Understanding What Kind of Off-Label Marketing Is Allowed Or Is Still Off-Limits Post-Amarin," ACI Forum on Promotional Review Compliance for Drugs & Devices, Philadelphia, Pennsylvania, January 2016
- Panelist, "Exploring The Top 5 Blunders In Food & Beverage Promotional Campaigns," Food & Beverage Litigation, Compliance & Regulatory Exchange, Chicago, Illinois, October 2015
- Presenter, "Managing risks: Assessing, mitigating and managing risks in the current environment," Third Annual Food Law Tele-Summit, October 2015
- Panelist, "Off-label marketing regulations and enforcement: Implications of the Caronia and Amarin rulings," Web Seminar, September 2015
- Moderator & Panelist, "2015 Litigation Trends Survey," Live Presentation, ACC America (South/Central Texas Chapter), San Antonio, Texas, July 2015
- Moderator, "Food Litigation Year in Review", The Food & Beverage Marketing & Advertising Law Summit, Chicago, Illinois, September 2014
- Panelist, "Advertising's Day in Court: The Supreme Court Takes a Stand on False Advertising," ALI-CLE Web Seminar, July 2014
- Moderator, "Tenth Annual Litigation Trends Survey findings," Web Seminar, June 2014
- Moderator, "Bringing Efficiency and Predictability to Litigation," Live Presentation, ACC America (South/Central Texas Chapter), San Antonio, Texas, December 2012
- Moderator, "Fulbright Litigation Trends," Live Presentation, ACC America (South/Central Texas Chapter), San Antonio, Texas, December 2011
- Moderator, "The ABCs of NDAs," ACC America (South/Central Texas Chapter) Roundtable, San Antonio, TX, August 2011
- Moderator, "Corporate Compliance Best Practices: Do's and Don'ts," ACC America (South/Central Texas Chapter) Roundtable, San Antonio, TX, August 2010
- Presenter, "Advertising and Promotion: Employing the Competitor Complaint Avenue to Your Advantage," ACI Corporate Counsel Forum on Advertising & Promotion for the Pharmaceutical Industry, New York, NY, November 2008
- Presenter, "Generic Drug Substitution: A Legal Perspective," Annual Meeting, Association of Consultant Pharmacists, November 2002
- American Bar Association
- California Bar Association
- San Antonio Bar Association
- National MS Society
- Cystic Fibrosis Foundation
Publication | April 5, 2021
Publication | February 10, 2021
Publication | January 26, 2021
The 2021 Appropriations Act: Fundamental changes to trademark and copyright law and the implications for IP owners
Publication | December 28, 2020